Display options
Cite
Lee MS, Lee J, Lee S, et al. Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget. 2018;9(8):7961-7974doi: 10.18632/oncotarget.24091.
Lee, M. S., Lee, J., Lee, S., Yoo, S. M., Kim, J. H., Kim, W. T., Kim, W. J., & Park, J. (2018). Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget, 9(8), 7961-7974. https://doi.org/10.18632/oncotarget.24091
Lee, Myung-Shin, et al. "Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer." Oncotarget vol. 9,8 (2018): 7961-7974. doi: https://doi.org/10.18632/oncotarget.24091
Lee MS, Lee J, Lee S, Yoo SM, Kim JH, Kim WT, Kim WJ, Park J. Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget. 2018 Jan 08;9(8):7961-7974. doi: 10.18632/oncotarget.24091. eCollection 2018 Jan 30. PMID: 29487706; PMCID: PMC5814273.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Jan 08;9(8):7961-7974. doi: 10.18632/oncotarget.24091. eCollection 2018 Jan 30.

Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer.

Oncotarget

Myung-Shin Lee, Jisu Lee, Suhyuk Lee, Seung-Min Yoo, Joo Heon Kim, Won Tae Kim, Wun-Jae Kim, Jinsung Park

Affiliations

  1. Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, South Korea.
  2. Department of Pathology, Eulji University School of Medicine, Daejeon, South Korea.
  3. Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea.
  4. Department of Urology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, South Korea.

PMID: 29487706 PMCID: PMC5814273 DOI: 10.18632/oncotarget.24091

Abstract

Heat shock protein 27 (HSP27) is highly expressed in many cancers, and its prognostic and predictive value has been reported. HSP27 knockdown using siRNA or OGX-427 (an anti-sense oligonucleotide sequence targeting HSP27) is reported to have anti-cancer effects and to enhance chemosensitivity of cancer cells to chemotherapeutic agents. However, conflicting results have been reported regarding the clinical significance of HSP27 in bladder cancer (BC). Furthermore, long-term suppression of HSP27 has not been investigated in BC. In this study, we investigated the association between HSP27 expression and BC characteristics in 132 BC patient samples, as well as its prognostic value to determine the potential of HSP27 as a clinical biomarker. Additionally, we applied five different shRNAs targeting HSP27 in three invasive BC cell lines to analyze the long-term knockdown effects of HSP27. Our study revealed a significant association between HSP27 expression and adverse pathological characteristics such as high-stage and -grade BC. However, HSP27 expression was not associated with clinical outcomes such as tumor recurrence, progression, and patient survival. Interestingly, although our shRNAs had obvious knockdown effects on HSP27 in BC cells, we did not find consistent effects on apoptosis of BC cells or chemotherapeutic sensitivity of BC cells to cisplatin. Therefore, although HSP27 may be a predictor of adverse pathological characteristics in BC, its role as a prognostic biomarker and therapeutic target seems to be limited.

Keywords: biomarkers; bladder cancer; heat shock protein 27; prognosis; shRNA

Conflict of interest statement

CONFLICTS OF INTEREST None.

References

  1. Breast Cancer Res Treat. 1999 Jul;56(2):187-96 - PubMed
  2. Urology. 1993 Oct;42(4):379-82 - PubMed
  3. Springerplus. 2016 Jul 25;5(1):1165 - PubMed
  4. Oncol Lett. 2010 Nov;1(6):1011-1016 - PubMed
  5. Histopathology. 2013 Apr;62(5):788-98 - PubMed
  6. Oncotarget. 2015 Nov 24;6(37):40370-84 - PubMed
  7. Mol Med. 2011 May-Jun;17(5-6):478-85 - PubMed
  8. Ann Oncol. 2016 Jun;27(6):1116-22 - PubMed
  9. PLoS One. 2015 Apr 27;10(4):e0125405 - PubMed
  10. BJU Int. 2006 Nov;98(5):1082-9 - PubMed
  11. Int J Biol Markers. 2008 Oct-Dec;23(4):214-8 - PubMed
  12. Mol Cancer Ther. 2007 Jan;6(1):299-308 - PubMed
  13. BJU Int. 2008 Aug 5;102(5):610-6 - PubMed
  14. Mol Ther. 2009 Aug;17(8):1387-94 - PubMed
  15. World J Urol. 2009 Apr;27(2):277-83 - PubMed
  16. Eur J Cancer. 1995 Oct;31A(11):1840-6 - PubMed
  17. Hum Pathol. 2014 Sep;45(9):1830-8 - PubMed
  18. Nature. 2014 Mar 20;507(7492):315-22 - PubMed
  19. J Biol Chem. 1993 Jan 25;268(3):1517-20 - PubMed
  20. Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7 - PubMed
  21. Mol Cancer Ther. 2009 Aug;8(8):2402-11 - PubMed
  22. Int J Urol. 2006 Feb;13(2):142-7 - PubMed
  23. Ann N Y Acad Sci. 2000;926:126-31 - PubMed
  24. Mol Cell Endocrinol. 2016 Aug 15;431:71-87 - PubMed
  25. Cell Stress Chaperones. 2005 Summer;10(2):86-103 - PubMed
  26. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  27. J Clin Oncol. 2001 Feb 1;19(3):666-75 - PubMed
  28. Theranostics. 2016 Feb 17;6(4):558-70 - PubMed
  29. Mol Med Rep. 2010 Nov-Dec;3(6):953-8 - PubMed
  30. Cell Mol Life Sci. 2018 Mar;75(5):797-814 - PubMed
  31. Biochem Biophys Res Commun. 1997 Dec 8;241(1):187-92 - PubMed
  32. Br J Cancer. 2004 Feb 9;90(3):578-81 - PubMed
  33. Cancer Res. 2013 May 15;73(10 ):3109-19 - PubMed
  34. Cancer. 2003 Sep 1;98(5):970-7 - PubMed
  35. Cell Death Dis. 2011 Oct 20;2:e221 - PubMed
  36. Pancreatology. 2013 Nov-Dec;13(6):564-9 - PubMed
  37. Mol Cancer Ther. 2015 May;14(5):1107-16 - PubMed
  38. Cancer. 2014 Mar 1;120(5):652-63 - PubMed
  39. Philos Trans R Soc Lond B Biol Sci. 1978 May 11;283(997):391-406 - PubMed
  40. J Clin Oncol. 1998 Nov;16(11):3576-83 - PubMed

Publication Types